Brief Summary of Talk
Antibiotic Development: Fight with the Wind-mills?
Antibiotic resistance, particularly in Gram-negative hospital pathogens, has become a global public health threat. The resistance reduces the lifespan of antibacterial agents, leading to the requirement for a steady supply of new antibiotics. Despite the huge need for new antibacterial agents, their commercial development remains limited. A new private-public partnership program New Drugs for Bad Bugs (ND4BB) has been launched by the European Commission and EFPIA to address both scientific and commercial bottleneck in antibacterial drug discovery. Participation of Latvian scientists in the ENABLE project of the ND4BB program is highlighted in the presentation.